SEC Tracker
Get the app

Outlook Therapeutics OTLK

Outlook Therapeutics Q2 FY25: net loss $46.4M; diluted EPS −$1.50

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Outlook Therapeutics reported for Q2 FY25, the quarter ended Mar 31, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$46.4MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$1.50No year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$7.6MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  4. Cash from operations−$16.6MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Outlook Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. OnKure Therapeutics OKUR public float $28M, Jun 30, 2025
  2. Palatin Technologies PTN public float $26M, Dec 31, 2025
  3. Scynexis SCYX public float $26M, Jun 30, 2025
  4. Champions Oncology CSBR public float $29M, Oct 31, 2025
  5. Rockwell Medical RMTI public float $29M, Jun 30, 2025